Please assess the completion status of the following clinical trial:

Trial Title: Investigation of the Superiority Effect of Desmopressin to Placebo in Terms of Night Voids Reduction in Nocturia Adult Female Patients

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Written informed consent prior to performance of any trial-related activity~* Female sex 18 years of age or older~* At least 2 voids every night in a consecutive 3-day period during the screening period~Exclusion Criteria:~1. Evidence of severe daytime voiding dysfunction defined as:~   * Urge urinary incontinence (more than 1 episode/day in the 3-day diary period)~  * Urgency (more than 1 episode/day in the 3-day diary period)~  * Frequency (more than 8 daytime voids/day in the 3-day diary period)~2. Interstitial cystitis~3. Urinary retention or a post void residual volume in excess of 150 mL as confirmed by bladder ultrasound performed after suspicion of urinary retention~4. Habitual or psychogenic polydipsia (fluid intake resulting in a urine production exceeding 40 mL/kg/24 hours)~5. Central or nephrogenic diabetes insipidus~6. Syndrome of inappropriate anti-diuretic hormone secretion~7. Current or a history of urologic malignancies e.g. bladder cancer~8. Genitourinary tract pathology e.g., infection or stone in the bladder and urethra causing symptoms~9. Neurogenic detrusor activity (detrusor overactivity).~10. Suspicion or evidence of cardiac failure~11. Uncontrolled hypertension~12. Uncontrolled diabetes mellitus~13. Hyponatraemia: Serum sodium level must be within normal limits~14. Renal insufficiency: Serum creatinine must be within normal limits and estimated glomerular filtration rate must be more than or equal to 50 mL/min~15. Hepatic and/or biliary diseases: Aspartate aminotransferase (AST) and/or alanine aminotransferase (ALT) levels must not be more than twice the upper limit of normal range. Total bilirubin level must not be more than 1.5 mg/dL~16. History of obstructive sleep apnea~17. Previous desmopressin treatment for nocturia~18. Treatment with another investigational product within 3 months prior to screening~19. Concomitant treatment with any prohibited medication e.g., loop diuretics (furosemide, torsemide, ethacrynic acid) and any other investigational drug~20. Pregnancy, breastfeeding, or a plan to become pregnant during the period of the clinical trial. Subjects of reproductive age must have documentation of a reliable method of contraception. All pre-and perimenopausal subjects have to perform pregnancy tests. Amenorrhea of more than 12 months' duration based on the reported date of the last menstrual period is sufficient documentation of post-menopausal status and does not require a pregnancy test~21. Known alcohol or substance abuse~22. Work or lifestyle that may interfere with regular nighttime sleep e.g., shift workers~23. Any other medical condition, laboratory abnormality, psychiatric condition, mental incapacity, or language barrier that, in the judgment of the Investigator, would impair participation in the trial

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Desmopressin 25 μg (Type: EXPERIMENTAL): Participants took 1 orally disintegrating tablet of desmopressin 25 μg every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.
- Placebo (Type: PLACEBO_COMPARATOR): Participants took 1 orally disintegrating tablet of placebo every night approximately 1 hour before bedtime for the entire duration of the 3-month treatment period.

Based on this trial design, predict the completion outcome and termination type (if applicable).